{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T15:20:47Z","timestamp":1791991247582,"version":"4.4.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"DOI":"10.1007\/s40618-025-02552-1","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T06:48:49Z","timestamp":1739947729000},"page":"1483-1493","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Clinical and biological heterogeneity of Grade 2 digestive neuroendocrine neoplasms: prognostic significance of the 10% Ki-67 index cutoff and implications for treatment strategies. A longitudinal study"],"prefix":"10.1007","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3214-8192","authenticated-orcid":false,"given":"Sara","family":"Massironi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Coltro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Dell\u2019Anna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paoletta","family":"Preatoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"Danese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,19]]},"reference":[{"issue":"4","key":"2552_CR1","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.path.2019.08.007","volume":"12","author":"N Patel","year":"2019","unstructured":"Patel N, Barbieri A, Gibson J (2019) Neuroendocrine tumors of the gastrointestinal tract and pancreas. Surg Pathol Clin 12(4):1021\u20131044","journal-title":"Surg Pathol Clin"},{"issue":"1","key":"2552_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/CCO.0b013e3282f1c595","volume":"20","author":"BI Gustafsson","year":"2008","unstructured":"Gustafsson BI, Kidd M, Modlin IM (2008) Neuroendocrine tumors of the diffuse neuroendocrine system. Curr Opin Oncol 20(1):1\u201312","journal-title":"Curr Opin Oncol"},{"issue":"35","key":"2552_CR3","doi-asserted-by":"publisher","first-page":"5377","DOI":"10.3748\/wjg.14.5377","volume":"14","author":"S Massironi","year":"2008","unstructured":"Massironi S, Sciola V, Peracchi M, Ciafardini C, Spampatti MP, Conte D (2008) Neuroendocrine tumors of the gastro-entero-pancreatic system. World J Gastroenterol 14(35):5377\u20135384","journal-title":"World J Gastroenterol"},{"key":"2552_CR4","doi-asserted-by":"publisher","unstructured":"Manneh Kopp R, Espinosa-Olarte P, Alonso-Gordoa T (2022) Diagnosis in neuroendocrine neoplasms: from Molecular Biology to Molecular Imaging. Cancers (Basel) 14(10):2514. https:\/\/doi.org\/10.3390\/cancers14102514","DOI":"10.3390\/cancers14102514"},{"key":"2552_CR5","doi-asserted-by":"publisher","unstructured":"Vocino Trucco G, Volante M (2024) Changes in categorization or nomenclature within neuroendocrine tumors. Endocr Relat Cancer 31(8):e240004. https:\/\/doi.org\/10.1530\/ERC-24-0004","DOI":"10.1530\/ERC-24-0004"},{"issue":"10","key":"2552_CR6","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","volume":"3","author":"A Dasari","year":"2017","unstructured":"Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y et al (2017) Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol 3(10):1335\u20131342","journal-title":"JAMA Oncol"},{"key":"2552_CR7","doi-asserted-by":"publisher","unstructured":"Kos-Kud\u0142a B, Casta\u00f1o JP, Denecke T, Grande E, Kjaer A, Koumarianou A et al (2023) European neuroendocrine Tumour Society (ENETS) 2023 guidance paper for nonfunctioning pancreatic neuroendocrine tumours. J Neuroendocrinol 35(12):e13343. https:\/\/doi.org\/10.1111\/jne.13343","DOI":"10.1111\/jne.13343"},{"issue":"8","key":"2552_CR8","doi-asserted-by":"publisher","first-page":"e13318","DOI":"10.1111\/jne.13318","volume":"35","author":"J Hofland","year":"2023","unstructured":"Hofland J, Falconi M, Christ E, Casta\u00f1o JP, Faggiano A, Lamarca A et al (2023) European Neuroendocrine Tumor Society 2023 guidance paper for functioning pancreatic neuroendocrine tumour syndromes. J Neuroendocrinol 35(8):e13318","journal-title":"J Neuroendocrinol"},{"key":"2552_CR9","doi-asserted-by":"publisher","unstructured":"Panzuto F, Ramage J, Pritchard DM, van Velthuysen MF, Schrader J, Begum N et al (2023) European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for gastroduodenal neuroendocrine tumours (NETs) G1-G3. J Neuroendocrinol 35(8):e13306. https:\/\/doi.org\/10.1111\/jne.1330","DOI":"10.1111\/jne.1330"},{"issue":"6","key":"2552_CR10","doi-asserted-by":"publisher","first-page":"e13309","DOI":"10.1111\/jne.13309","volume":"35","author":"A Rinke","year":"2023","unstructured":"Rinke A, Ambrosini V, Dromain C, Garcia-Carbonero R, Haji A, Koumarianou A et al (2023) European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for colorectal neuroendocrine tumours. J Neuroendocrinol 35(6):e13309","journal-title":"J Neuroendocrinol"},{"issue":"10","key":"2552_CR11","doi-asserted-by":"publisher","first-page":"e13332","DOI":"10.1111\/jne.13332","volume":"35","author":"G Kaltsas","year":"2023","unstructured":"Kaltsas G, Walter T, Knigge U, Toumpanakis C, Santos AP, Begum N et al (2023) European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for appendiceal neuroendocrine tumours (aNET). J Neuroendocrinol 35(10):e13332","journal-title":"J Neuroendocrinol"},{"key":"2552_CR12","doi-asserted-by":"publisher","unstructured":"Sultana Q, Kar J, Verma A, Sanghvi S, Kaka N, Patel N et al (2023) A Comprehensive Review on Neuroendocrine neoplasms: Presentation, Pathophysiology and Management. J Clin Med 12(15):5138. https:\/\/doi.org\/10.3390\/jcm12155138","DOI":"10.3390\/jcm12155138"},{"issue":"11","key":"2552_CR13","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/nrclinonc.2016.85","volume":"13","author":"M Kidd","year":"2016","unstructured":"Kidd M, Modlin I, \u00d6berg K (2016) Towards a new classification of gastroenteropancreatic neuroendocrine neoplasms. Nat Rev Clin Oncol 13(11):691\u2013705","journal-title":"Nat Rev Clin Oncol"},{"key":"2552_CR14","doi-asserted-by":"crossref","unstructured":"Pasaoglu E, Dursun N, Ozyalvacli G, Hacihasanoglu E, Behzatoglu K, Calay O (2015) Ann Diagn Pathol 19(2):81\u201387Comparison of World Health Organization 2000\/2004 and World Health Organization 2010 classifications for gastrointestinal and pancreatic neuroendocrine tumors","DOI":"10.1016\/j.anndiagpath.2015.01.001"},{"issue":"2","key":"2552_CR15","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/his.13975","volume":"76","author":"ID Nagtegaal","year":"2020","unstructured":"Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher P et al (2020) The 2019 WHO classification of tumours of the digestive system. Histopathology 76(2):182\u2013188","journal-title":"Histopathology"},{"key":"2552_CR16","doi-asserted-by":"publisher","unstructured":"Houpt JA, Liu E, Wang H, Cecchini MJ, Ling C, Zhang Q (2024) Determination of Ki-67 indices in neuroendocrine tumours of the gastrointestinal tract: the past, the present, and the future. Virchows Arch. https:\/\/doi.org\/10.1007\/s00428-024-03963-w","DOI":"10.1007\/s00428-024-03963-w"},{"issue":"3","key":"2552_CR17","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s12022-023-09785-x","volume":"34","author":"A Vanoli","year":"2023","unstructured":"Vanoli A (2023) The spectrum of neuroendocrine neoplasia: a practical Approach to diagnosis, classification and therapy by Sylvia L. Asa, Stefano La Rosa, Ozgur Mete. Endocr Pathol 34(3):361\u2013362","journal-title":"Endocr Pathol"},{"key":"2552_CR18","doi-asserted-by":"crossref","unstructured":"Buchstab O, Kn\u00f6sel T, [Current, WHO classification (2022) of neuroendocrine neoplasms]. Radiologie (Heidelb). 2024;64(7):531-5","DOI":"10.1007\/s00117-024-01295-z"},{"issue":"1","key":"2552_CR19","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s12022-022-09708-2","volume":"33","author":"G Rindi","year":"2022","unstructured":"Rindi G, Mete O, Uccella S, Basturk O, La Rosa S, Brosens LAA et al (2022) Overview of the 2022 WHO classification of neuroendocrine neoplasms. Endocr Pathol 33(1):115\u2013154","journal-title":"Endocr Pathol"},{"issue":"1","key":"2552_CR20","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3348\/kjr.2018.0040","volume":"20","author":"J Choe","year":"2019","unstructured":"Choe J, Kim KW, Kim HJ, Kim DW, Kim KP, Hong SM et al (2019) What is New in the 2017 World Health Organization Classification and 8th American Joint Committee on Cancer Staging System for pancreatic neuroendocrine neoplasms? Korean J Radiol 20(1):5\u201317","journal-title":"Korean J Radiol"},{"issue":"4","key":"2552_CR21","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1677\/erc.1.01017","volume":"12","author":"F Panzuto","year":"2005","unstructured":"Panzuto F, Nasoni S, Falconi M, Corleto VD, Capurso G, Cassetta S et al (2005) Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer 12(4):1083\u20131092","journal-title":"Endocr Relat Cancer"},{"key":"2552_CR22","doi-asserted-by":"publisher","unstructured":"Zappi A, Persano I, Galvani L, Parlagreco E, Andrini E, Campana D et al (2023) Chemotherapy in well differentiated neuroendocrine tumors (NET) G1, G2, and G3: a narrative review. J Clin Med 12(2):717. https:\/\/doi.org\/10.3390\/jcm12020717","DOI":"10.3390\/jcm12020717"},{"key":"2552_CR23","doi-asserted-by":"publisher","unstructured":"Joseph NM, Umetsu SE, Kim GE, Terry M, Perry A, Bergsland E et al (2024) Progression of low-Grade neuroendocrine tumors (NET) to high-Grade neoplasms harboring the NEC-Like co-alteration of RB1 and TP53. Endocr Pathol 35(4):325\u2013337. https:\/\/doi.org\/10.1007\/s12022-024-09835-y","DOI":"10.1007\/s12022-024-09835-y"},{"issue":"12","key":"2552_CR24","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1093\/jjco\/hyab144","volume":"51","author":"B Yuan","year":"2021","unstructured":"Yuan B, Shi Y, Li Y, Tan H, Jiao P, Su W et al (2021) Ki-67 index of 5% could better predict the clinical prognosis of well-differentiated pancreatic neuroendocrine tumours. Jpn J Clin Oncol 51(12):1708\u20131714","journal-title":"Jpn J Clin Oncol"},{"issue":"1","key":"2552_CR25","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/his.14172","volume":"78","author":"AJ Gill","year":"2021","unstructured":"Gill AJ (2021) Why did they change that? Practical implications of the evolving classification of neuroendocrine tumours of the gastrointestinal tract. Histopathology 78(1):162\u2013170","journal-title":"Histopathology"},{"issue":"2","key":"2552_CR26","doi-asserted-by":"publisher","first-page":"188637","DOI":"10.1016\/j.bbcan.2021.188637","volume":"1876","author":"M Shi","year":"2021","unstructured":"Shi M, Fan Z, Xu J, Yang J, Li Y, Gao C et al (2021) Gastroenteropancreatic neuroendocrine neoplasms G3: novel insights and unmet needs. Biochim Biophys Acta Rev Cancer 1876(2):188637","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"5","key":"2552_CR27","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1097\/PAS.0000000000000408","volume":"39","author":"O Basturk","year":"2015","unstructured":"Basturk O, Yang Z, Tang LH, Hruban RH, Adsay V, McCall CM et al (2015) The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms. Am J Surg Pathol 39(5):683\u2013690","journal-title":"Am J Surg Pathol"},{"key":"2552_CR28","doi-asserted-by":"publisher","unstructured":"Mohamed A, Trybula M, Asa SL, Halfdanarson TR, Sonbol MB (2024) Management of advanced high grade gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): comprehensive review of the current literature. Endocr Relat Cancer 31(10):e240025. https:\/\/doi.org\/10.1530\/ERC-24-0025","DOI":"10.1530\/ERC-24-0025"},{"issue":"10","key":"2552_CR29","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1007\/s11605-020-04651-1","volume":"24","author":"H Shi","year":"2020","unstructured":"Shi H, Chen L, Meng L, Zhang Q, Lin Y, Lin R et al (2020) The role of Ki-67 index cut-off of 55% and differentiation in redefining NET and NEC for Grade 3 gastrointestinal neuroendocrine neoplasms. J Gastrointest Surg 24(10):2302\u20132305","journal-title":"J Gastrointest Surg"},{"issue":"10","key":"2552_CR30","doi-asserted-by":"publisher","first-page":"7001","DOI":"10.1245\/s10434-024-15632-y","volume":"31","author":"OC Eren","year":"2024","unstructured":"Eren OC, Bagci P, Balci S, Ohike N, Saka B, Sokmensuer C et al (2024) Subgrading of G2 pancreatic neuroendocrine tumors as 2A (Ki67 3% to <\u200910%) versus 2B (10% to \u2264\u200920%) identifies behaviorally distinct subsets in keeping with the Evolving Management Protocols. Ann Surg Oncol 31(10):7001\u20137011","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"2552_CR31","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","volume":"31","author":"M Pavel","year":"2020","unstructured":"Pavel M, \u00d6berg K, Falconi M, Krenning EP, Sundin A, Perren A et al (2020) Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 31(7):844\u2013860","journal-title":"Ann Oncol"},{"issue":"3","key":"2552_CR32","doi-asserted-by":"publisher","first-page":"548","DOI":"10.21037\/jgo.2020.03.07","volume":"11","author":"OC Taskin","year":"2020","unstructured":"Taskin OC, Clarke CN, Erkan M, Tsai S, Evans DB, Adsay V (2020) Pancreatic neuroendocrine neoplasms: current state and ongoing controversies on terminology, classification and prognostication. J Gastrointest Oncol 11(3):548\u2013558","journal-title":"J Gastrointest Oncol"},{"issue":"17","key":"2552_CR33","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1200\/JCO.2010.33.0688","volume":"29","author":"F Panzuto","year":"2011","unstructured":"Panzuto F, Boninsegna L, Fazio N, Campana D, Pia Brizzi M, Capurso G et al (2011) Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression. J Clin Oncol 29(17):2372\u20132377","journal-title":"J Clin Oncol"},{"issue":"5","key":"2552_CR34","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1007\/s00330-014-3532-z","volume":"25","author":"DW Kim","year":"2015","unstructured":"Kim DW, Kim HJ, Kim KW, Byun JH, Song KB, Kim JH et al (2015) Neuroendocrine neoplasms of the pancreas at dynamic enhanced CT: comparison between grade 3 neuroendocrine carcinoma and grade 1\/2 neuroendocrine tumour. Eur Radiol 25(5):1375\u20131383","journal-title":"Eur Radiol"},{"issue":"1","key":"2552_CR35","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1186\/s12885-024-13117-5","volume":"24","author":"H Gao","year":"2024","unstructured":"Gao H, Zhang W, Li Z, Liu W, Liu M, Zhuo Q et al (2024) Distinctive grade based on Ki67 index and immune microenvironment of metastatic pancreatic neuroendocrine tumors responding to capecitabine plus temozolomide. BMC Cancer 24(1):1362","journal-title":"BMC Cancer"},{"issue":"5","key":"2552_CR36","first-page":"362","volume":"63","author":"W Foltyn","year":"2012","unstructured":"Foltyn W, Zaj\u0119cki W, Marek B, Kajdaniuk D, Siemi\u0144ska L, Zemczak A et al (2012) The value of the Ki-67 proliferation marker as a prognostic factor in gastroenteropancreatic neuroendocrine tumours. Endokrynol Pol 63(5):362\u2013366","journal-title":"Endokrynol Pol"},{"issue":"6","key":"2552_CR37","doi-asserted-by":"publisher","first-page":"734","DOI":"10.3109\/00365521.2014.903432","volume":"49","author":"R Boyar Cetinkaya","year":"2014","unstructured":"Boyar Cetinkaya R, Vatn M, Aabakken L, Bergestuen DS, Thiis-Evensen E (2014) Survival and prognostic factors in well-differentiated pancreatic neuroendocrine tumors. Scand J Gastroenterol 49(6):734\u2013741","journal-title":"Scand J Gastroenterol"},{"issue":"9","key":"2552_CR38","doi-asserted-by":"publisher","first-page":"3542","DOI":"10.1245\/s10434-020-08377-x","volume":"27","author":"NA Trikalinos","year":"2020","unstructured":"Trikalinos NA, Chatterjee D, Lee J, Liu J, Williams G, Hawkins W et al (2020) Accuracy of Grading in pancreatic neuroendocrine neoplasms and Effect on Survival estimates: an institutional experience. Ann Surg Oncol 27(9):3542\u20133550","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"2552_CR39","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1097\/MPA.0000000000001693","volume":"49","author":"H Shi","year":"2020","unstructured":"Shi H, Chen L, Zhang Q, Lin Y, Jiang C, Yao H et al (2020) Concordance between the Ki-67 Index Cutoff Value of 55% and differentiation in neuroendocrine tumor and neuroendocrine carcinoma in Grade 3 pancreatic neuroendocrine neoplasms. Pancreas 49(10):1378\u20131382","journal-title":"Pancreas"},{"key":"2552_CR40","doi-asserted-by":"publisher","first-page":"151586","DOI":"10.1016\/j.anndiagpath.2020.151586","volume":"48","author":"W Huang","year":"2020","unstructured":"Huang W, Nebiolo C, Esbona K, Hu R, Lloyd R (2020) Ki67 index and mitotic count: correlation and variables affecting the accuracy of the quantification in endocrine\/neuroendocrine tumors. Ann Diagn Pathol 48:151586","journal-title":"Ann Diagn Pathol"},{"issue":"10","key":"2552_CR41","doi-asserted-by":"publisher","first-page":"7068","DOI":"10.1245\/s10434-024-15728-5","volume":"31","author":"OC Eren","year":"2024","unstructured":"Eren OC, Bagci P, Balci S, Ohike N, Saka B, Sokmensuer C et al (2024) ASO author reflections: Prognostic Value of Subgrading G2 pancreatic neuroendocrine tumors as 2A versus 2B. Ann Surg Oncol 31(10):7068\u20137069","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"2552_CR42","doi-asserted-by":"publisher","first-page":"100017","DOI":"10.1016\/j.modpat.2022.100017","volume":"36","author":"M Zhang","year":"2023","unstructured":"Zhang M, Tan C, Wang X, Ding X, Zhang B, Yang Z et al (2023) Digital Image Analysis of Ki67 heterogeneity improves the diagnosis and prognosis of gastroenteropancreatic neuroendocrine neoplasms. Mod Pathol 36(1):100017","journal-title":"Mod Pathol"},{"issue":"1","key":"2552_CR43","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s12022-023-09755-3","volume":"34","author":"RS La Diagnostic","year":"2023","unstructured":"La Diagnostic RS (2023) Prognostic, and predictive role of Ki67 proliferative index in neuroendocrine and endocrine neoplasms: past, Present, and Future. Endocr Pathol 34(1):79\u201397","journal-title":"Endocr Pathol"},{"issue":"8","key":"2552_CR44","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.21037\/tcr-23-248","volume":"12","author":"Z Tao","year":"2023","unstructured":"Tao Z, Xue R, Wei Z, Qin L, Bai R, Liu N et al (2023) The assessment of Ki-67 for prognosis of gastroenteropancreatic neuroendocrine neoplasm patients: a systematic review and meta-analysis. Transl Cancer Res 12(8):1980\u20131991","journal-title":"Transl Cancer Res"},{"issue":"11","key":"2552_CR45","doi-asserted-by":"publisher","first-page":"e676","DOI":"10.1097\/RLU.0000000000004365","volume":"47","author":"S Choudhury","year":"2022","unstructured":"Choudhury S, Agrawal A, Rangarajan V, Puranik A, Bal M, Chaudhari V et al (2022) Impact of FDG PET\/CT scan in changing management of well-differentiated neuroendocrine tumors with Ki67 Index Less Than or Equal to 5. Clin Nucl Med 47(11):e676\u2013e81","journal-title":"Clin Nucl Med"},{"issue":"18","key":"2552_CR46","doi-asserted-by":"publisher","first-page":"3090","DOI":"10.1002\/cncr.35463","volume":"130","author":"AJH Sedlack","year":"2024","unstructured":"Sedlack AJH, Varghese DG, Naimian A, Yazdian Anari P, Bodei L, Hallet J et al (2024) Update in the management of gastroenteropancreatic neuroendocrine tumors. Cancer 130(18):3090\u20133105","journal-title":"Cancer"},{"key":"2552_CR47","doi-asserted-by":"publisher","unstructured":"Sorbye H, Kong G, Grozinsky-Glasberg S, Strosberg J (2024) PRRT in high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). J Neuroendocrinol 2024:e13443. https:\/\/doi.org\/10.1111\/jne.13443","DOI":"10.1111\/jne.13443"},{"issue":"2","key":"2552_CR48","doi-asserted-by":"publisher","first-page":"188593","DOI":"10.1016\/j.bbcan.2021.188593","volume":"1876","author":"Y Zhu","year":"2021","unstructured":"Zhu Y, Zhu X, Tang C, Guan X, Zhang W (2021) Progress and challenges of immunotherapy in triple-negative breast cancer. Biochim Biophys Acta Rev Cancer 1876(2):188593","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"12","key":"2552_CR49","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","volume":"22","author":"JR Strosberg","year":"2021","unstructured":"Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A et al (2021) (177)Lu-Dotatate plus long-acting octreotide versus high\u2013dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol 22(12):1752\u20131763","journal-title":"Lancet Oncol"},{"issue":"10446","key":"2552_CR50","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","volume":"403","author":"S Singh","year":"2024","unstructured":"Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz PL et al (2024) [(177)Lu]Lu-DOTA-TATE plus long-acting octreotide versus high\u2013dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2\u20133, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet 403(10446):2807\u20132817","journal-title":"Lancet"},{"issue":"15","key":"2552_CR51","doi-asserted-by":"publisher","first-page":"6437","DOI":"10.7150\/thno.77219","volume":"12","author":"Y Jiang","year":"2022","unstructured":"Jiang Y, Liu Q, Wang G, Sui H, Wang R, Wang J et al (2022) Safety and efficacy of peptide receptor radionuclide therapy with (177)Lu-DOTA-EB-TATE in patients with metastatic neuroendocrine tumors. Theranostics 12(15):6437\u20136445","journal-title":"Theranostics"},{"issue":"9","key":"2552_CR52","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1097\/RLU.0000000000005330","volume":"49","author":"M Mileva","year":"2024","unstructured":"Mileva M, Van Bogaert C, Marin G, Danieli R, Artigas C, Levillain H et al (2024) 177 Lu-DOTATATE PRRT Safety and Organ-at-risk dosimetry in patients with gastroenteropancreatic neuroendocrine tumors: data from the prospective phase 2 LUMEN Study. Clin Nucl Med 49(9):847\u2013853","journal-title":"Clin Nucl Med"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-025-02552-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-025-02552-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-025-02552-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T05:50:36Z","timestamp":1751521836000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-025-02552-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,19]]},"references-count":52,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["2552"],"URL":"https:\/\/doi.org\/10.1007\/s40618-025-02552-1","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,19]]},"assertion":[{"value":"21 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Silvio Danese reports consultancy fees from AbbVie, Alimentiv, Allergan, Amgen, AstraZeneca, Athos Therapeutics, Biogen, Boehringer Ingelheim, Celgene, Celltrion, Eli Lilly, Enthera, Ferring Pharmaceuticals Inc., Gilead, Hospira, Inotrem, Janssen, Johnson & Johnson, MSD, Mundipharma, Mylan, Pfizer, Roche, Sandoz, Sublimity Therapeutics, Takeda, TiGenix, UCB Inc., and Vifor. Silvio Danese reports lecture fees from Abbvie, Amgen, Dr. Falk Pharma, Ferring Pharmaceuticals Inc., Gilead, Janssen, Mylan, Pfizer, and Takeda.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Sara Massironi conceived the study and wrote the final version of the manuscript. Camilla Gallo and Lorenzo Coltro was responsible for collecting the bibliography, gathering patient data, and obtaining informed consent from the participants. Paoletta Preatoni conducted the bibliographic research and collaborated with Sara Massironi on the statistical analysis. Camilla Gallo reviewed the paper and completed the bibliography. Silvio Danese played a key role in the study design and contributed to the final manuscript preparation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Contributions of authors"}},{"value":"The other authors declare no conflicts of interest concerning this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}